Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody

Journal of Clinical Investigation

Volumn 116, Issue 3, 2006, Pages 825-832

  Bales, Kelly R ^a,b   Tzavara, Eleni T ^a,c   Wu, Su ^a   Wade, Mark R ^a   Bymaster, Frank P ^a   Paul, Steven M ^a   Nomikos, George G ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN ANTIBODY M 266; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC NEUROPATHY; BINDING AFFINITY; CHOLINE UPTAKE; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; FEMALE; HABITUATION; HIPPOCAMPUS; MEMORY DISORDER; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; TRANSGENIC MOUSE; WILD TYPE;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; LEARNING; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; NEUROTRANSMITTER AGENTS; PEPTIDE FRAGMENTS; RNA, MESSENGER; SYNAPTOSOMES;

EID: 33644660826     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27120     Document Type: Article

References (39)

1. Perry, E., Walker, M., Grace, J., and Perry, R. 1999. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 22:273-280.
2. Bartus, R., Dean, R.L., Beer, B., and Lippa, A.S.1982. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:408-411.
3. Coyle, J.T., Price, D.L., and DeLong, M.R. 1983. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1184-1190.
4. Whitehouse, P.J., et al. 1981. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10:122-126.
5. Hardy, J., and Selkoe, D.J. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:353-356.
6. Selkoe, D.J. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741-766.
7. Walsh, D.M., et al. 2002. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:535-539.
8. Westerman, M.A., et al. 2002. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22:1858-1867.
9. McLean, C.A., et al. 1999. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46:860-866.
10. Lue, L.F., et al. 1999. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:853-862.
11. Wang, J., Dickson, D.W., Trojanowski, J.Q., and Lee, V.M. 1999. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 58:328-337.
12. Parvathy, S., et al. 2001. Correlation between Aβx-40-, Aβx-42-, and Aβx-43-containing amyloid plaques and cognitive decline. Arch. Neurol. 8:2025-2032.
13. Dodart, J.C., et al. 2002. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5:452-457.
14. Games, D., et al. 1995. Alzheimer-type pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:523-527.
15. Irizarry, M., et al. 1997. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 15:7053-7059.
16. German, D.G., et al. 2003. Cholinergic neuropathology in a mouse model of Alzheimer's disease. J. Comp. Neurol. 462:371-381.
17. Dodart, J.C., Mathis, C., Bales, K.R., and Paul, S.M. 1999. Behavioral disturbances in transgenic mice overexpressing the V717F β-amyloid precursor protein. Behav. Neurosci. 5:982-990.
18. Tzavara, E.T., et al. 2003. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol. Psychiatry. 8:673-679.
19. Yamamura, H., and Synder, S.H. 1972. Choline: high affinity uptake by rat brain synaptosomes. Science. 178:626-628.
20. Johnson-Wood, K., et al.1997. Amyloid precursor protein processing and Abeta 42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94:1550-1555.
21. Mesulam, M.M., and Mufson, E.J. 1984. Neural inputs into the nucleus basalis of the substantia inominata (Ch4) in the rhesus monkey. Brain. 104:253-274.
22. Simon, J., Atweh, S., and Kuhar, M. 1976. Sodium-dependent high affinity choline uptake: a regulatory step in the synthesis of acetylcholine J. Neurochem. 26:908-922.
23. DeMattos, R.B., et al. 2001. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of AD. Proc. Natl. Acad. Sci. U. S. A. 15:8850-8855.
24. Acquas, E., Wilson, C., and Fibiger, H.C. 1996. Conditioned and unconditioned stimuli increase frontal cortical and hippocampal acetylcholine release: effects of novelty, habituation, and fear. J. Neurosci. 16:3089-3096.
25. 1-42 binds to α7 nicotinic acetylcholine receptor with high affinity. J. Biol. Chem. 25:5626-5632.
26. Kamenetx, F., et al. 2003. APP processing and synaptic function. Neuron. 37:925-937.
27. Selkoe, D.J. 2002. Alzheimer's disease is a synaptic failure. Science. 298:789-791.
28. Cleary, J.P., et al. 2005. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 8:78-84.
29. Kotilinek, L.A., et al. 2002. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22:6331-6335.
30. Meziane, H., et al. 1998. Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice. Proc. Natl. Acad. Sci. U. S. A. 95:12683-12688.
31. DeKosky, S.T., et al. 2002. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 51:145-155.
32. Snyder, E.M., et al. 2005. Regulation of NMDA receptor trafficking by amyloid-β Nat. Neurosci. 8:1051-1058.
33. Slotkin, T.A., et al. 1990. Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. Proc. Natl. Acad. Sci. U. S. A. 87:2452-2455.
34. Brandon, E.P., et al. 2004. Choline transporter 1 maintains cholinergic function in choline acetyltransferase haploinsufficiency. J. Neurosci. 24:5459-5466.
35. Gates, J., Ferguson, S.M., Blakely, R.D., and Apparsundaram, S. 2004. Regulation of choline transporter surface expression and phosphorylation by protein kinase C and protein phosphatase 1/2A. J. Pharmacol. Exp. Therap. 310:536-545.
36. Wurtman, R.J. 1992. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci. 15:117-122.
37. Xu, J., et al. 2002. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8:600-606.
38. Nomikos, G.G., Arborelius, L., and Svensson, T.H. 1992. The novel 5-HT1A receptor antagonist (S)-UH-301 prevents (R) OH-DPAT-induced decrease in interstitial concentrations of serotonin in the rat hippocampus. Eur. J. Pharmacol. 216:373-378.
39. Bymaster, F.P., Perry, K.W., and Wong, D.T. 1985. Measurement of acetylcholine and choline in brain by HPLC with electrochemical detection. Life Sci. 237:1775-1781.